Pharmacy benefit management is the most commercially complex and politically contentious segment of American healthcare. The three largest PBMs — CVS Caremark, UnitedHealth OptumRx, and Cigna Evernorth/Express Scripts — collectively manage drug benefits for over 270 million Americans and control the formulary decisions, prior authorization requirements, and rebate negotiations that determine which drugs are prescribed and at what cost. Congressional scrutiny of PBM practices, the Inflation Reduction Act's drug pricing provisions, and biosimilar adoption are reshaping the competitive dynamics and commercial viability of the PBM business model.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• PBM Market Structure
• CVS Caremark, OptumRx, Express Scripts Competitive Comparison
• Drug Formulary Strategy
• Prior Authorization Reform
• Specialty Drug Management
• Rebate Transparency
• IRA Impact on PBM
• Biosimilar Adoption
Table of Contents
1. Executive Summary
2. Market Overview
3. PBM Market Structure
4. CVS Caremark, OptumRx, Express Scripts Competitive Comparison
5. Drug Formulary Strategy
6. Prior Authorization Reform
7. Specialty Drug Management
8. Rebate Transparency
9. IRA Impact on PBM
10. Biosimilar Adoption
11. Competitive Landscape
12. Regional Market Analysis
13. Strategic Conclusions and Recommendations
14. Appendix
List of Tables
Table 1. Market Overview and Key Data 2025
Table 2. Competitive Landscape 2025
Table 3-8. Topic-Specific Analysis Tables
Table 3. Leading Companies — Portfolio and Strategy Assessment 2025
Table 4. M&A and Partnership Activity 2023-2025
Table 5. Regional Analysis
Table 6. Key Risks and Mitigation Strategies
Companies Profiled
Caremark
Express Scripts
Magellan Rx
MedImpact
Navitus
OptimRx
Prime Therapeutics
